Phase 1/2a study of the IRAK4 inhibitor CA-4948 as monotherapy or in   combination with azacitidine or venetoclax in patients with   relapsed/refractory (R/R) acute myeloid leukemia or lyelodysplastic   syndrome.

Title:: Phase 1/2a study of the IRAK4 inhibitor CA-4948 as monotherapy or in combination with azacitidine or venetoclax in patients with relapsed/refractory (R/R) acute myeloid leukemia or lyelodysplastic syndrome.
Document type:: Meeting Abstract
Author(s):: Garcia-Manero, Guillermo; Winer, Eric S.; DeAngelo, Daniel J.; Tarantolo, Stefano R.; Sallman, David Andrew; Dugan, James; Groepper, Stefanie; Giagounidis, Aristoteles; Gotze, Katharina S.; Metzeler, Klaus; Li, Chia-Cheng; Zhou, Li; Martinez, Elizabeth; Lane, Maureen E.; Von Roemeling, Reinhard W.; Bohme, Matthias; Kubasch, Anne Sophie; Verma, Amit K.; Platzbecker, Uwe
Journal title abbreviation:: J Clin Oncol
Year:: 2022
Journal volume:: 40 Suppl S
Journal issue:: 16
Print-ISSN:: 0732-183X
TUM Institution:: Klinik und Poliklinik für Innere Medizin III, Hämatologie und Onkologie
BibTeX

Occurrences: